Table of Contents

INTRODUCTION

Characteristics of the Aging Process Relevant to Lipid Intervention

LIPOPROTEINS & AGING

Biochemistry and Metabolism of Lipoproteins

Changes of Lipoproteins with Aging

LIPIDS, CARDIOVASCULAR RISK AND AGING

Total Cholesterol, LDL Cholesterol and Non-HDL Cholesterol as Risk Factors

Other Lipids and Lipoproteins as Risk Factors

Inflammatory Markers as Risk Factors

LIPID INTERVENTION FOR CARDIOVASCULAR PREVENTION

Lifestyle Changes and Lipoproteins

Lipid Lowering Drugs and Cardiovascular Risk

LIPID LOWERING DRUGS AND CARDIOVASCULAR PREVENTION

Statin Cardiovascular Clinical Trials

Difficulties in Statin Clinical Trials

Statin clinical trials with outcomes other than cardiovascular acute events

Cardiovascular Trials with Other Lipid Lowering Drugs

Treatment of Hyperlipidemia-induced Pancreatitis

SAFETY OF LIPID LOWERING DRUGS IN THE ELDERLY

Pathophysiology of Drug Interaction and Toxicity

Muscle toxicity of lipid lowering drugs

Hepatotoxicity of lipid lowering drugs

Other toxicity of lipid lowering drugs

Cancer and lipid lowering drugs

Risk attributable to drug interaction

EPIDEMIOLOGY OF PRESCRIBING LIPID LOWERING DRUGS FOR THE ELDERLY

SHOULD LIPID LOWERING DRUGS BE PRESCRIBED FOR THE ELDERLY?